CAFC Reverses Patent Infringement Verdict Against Boston Scientific in UT Suit

WISECODE Take

On July 27, 2026, the CAFC reversed a patent verdict between the University of Texas and Boston Scientific (Case 24-2062). This debunks the myth that a jury's verdict guarantees a final win. Overly broad patent claims are highly vulnerable to being invalidated during appeal due to prior art. UT's Patent No. 6,596,296 was anticipated by Patent No. 5,364,627 (Song) from the chewing gum field. This proves that differing application fields do not prevent invalidation if the physical structures are identical. For medical device makers, defining a liquid coating as a fiber structure is unlikely to succeed in court; however, businesses not dealing with multi-layer composites remain unaffected. Zhidian offers patent portfolio health check services to help R&D heads mitigate such risks early. First, avoid overly abstract terms in claims and retain clear definitions and examples. Second, search across unrelated fields for identical physical structures to use as leverage against competitors' patents. Boston Scientific's reversal via critical expert testimony underscores that precise interpretation of technical details in prior art is the key to patent survival.